ClinicalTrials.gg
RecruitingNCT06155396Updated Feb 28, 2024

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

A Phase 2 interventional study of Disitamab Vedotin and Zimberelimab in Cervical Cancer, sponsored by RemeGen Co., Ltd.. Recruiting at 12 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
150th of 360
116 · median 90
Started
2024
with 60 others
Phase 2
137 of 455
71 open now
Primary completion
2027-06
later than 160 of 239 live
Registered
311th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 150th largest by planned enrollment of the 360 interventional ones that give a count, is one of 61 that started in 2024, is one of 137 in phase 2, reaches primary completion later than 160 of the 239 other live ones, and was the 311th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer

Read the detailed description

This is a Phase II, Single-Arm ,multicenter, open-label clinical trial designed to evaluate safety and efficacy of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer.The HER2-expressing is defined as: the HER2 IHC 3+ or 2+, or 1+.subjects with IHC 2+ require testing for FISH.

03

Conditions studied

  • Cervical Cancer

Keywords

  • HER2-expressing
  • Recurrent Cervical Cancer
  • Metastatic Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. a)Patients with confirmed -expressing recurrent or cervical cancer who have failed at least 1 line of standard platinum-containing therapy ; b) Not suitable for surgery or radiotherapy;
  2. Voluntarily agreed to participate in the study and signed an form.
  3. Female, age ≥ 18 years
  4. Expected survival ≥ 12 weeks
  5. Central laboratory confirmation of HER2 expression: IHC 1+, 2+, or 3+; subjects with IHC 2+ require testing for FISH.
  6. Central laboratory confirmation of expression
  7. according to 1.1 standard
  8. physical condition 0 or 1 point
  9. Adequate organ function, criteria should be met during the screening period

    1. ≥1,500/µL
    2. count ≥100,000/μL
    3. ≥9.0 g/dL
    4. total ≤1.5 × upper limit normal () OR direct bilirubin ≤ULN for subjects with total bilirubin >1.5 × ULN. Serum bilirubin ≤3× ULN for subjects with Gilbert's disease
    5. ≥50 mL/min (measured by the Cockcroft-Gault formula as applicable, or 24-hour urine).
    6. and AST ≤2.5× ULN without liver metastases or ≤5× ULN with liver metastases
    7. ≥>50%
  10. Female subjects should be surgically sterilised, or agree to use at least one medically approved method during and for 6 months after the end of the study treatment period, must have had a negative blood pregnancy test within 7 days prior to study entry, and must be non-lactating.
  11. Willingness and ability to comply with trial and follow-up procedure arrangements.

Exclusion criteria

Exclusion Criteria:

  1. Have central nervous system and/or carcinomatous meningitis.
  2. Received anti-tumour therapy or participated in another clinical study treatment within 4 weeks prior to the start of study treatment.
  3. Toxicity due to previous antineoplastic therapy has not recovered to (version 5.0) grade 0-1.
  4. Major surgery with incomplete recovery within 4 weeks prior to start of study dosing.
  5. Serum virology examination (based on the normal value of the research center) :

    1. test results were positive, and HBV DNA copy number was positive;
    2. HCVAb test results were positive ( PCR test results were negative only to be included in this study);
    3. HIVAb tested positive
  6. Have received a live or within 4 weeks prior to the start of study dosing; or plan to receive any vaccine during the study period
  7. Grade 3 or higher heart failure
  8. History of gastrointestinal perforation and/or fistula within the previous 6 months
  9. Serious arterial/venous thrombotic event or cardiovascular accident within 1 year prior to study drug administration
  10. Presence of active or progressive infection requiring systemic therapy, with severe infection within 4 weeks prior to first dose;
  11. Active TB.
  12. Presence of systemic disease not under stable control as judged by the investigator.
  13. History of interstitial pneumonia, obstructive lung disease, drug-induced pneumonia, radiation pneumonia, idiopathic pneumonia or active pneumonia.
  14. pyelonephrosis cannot be alleviated by ureteral stents or percutaneous drainage.
  15. Presence of active disease requiring systemic therapy within 2 years prior to the start of study drug administration, allowing for relevant alternative therapy.
  16. Other within 5 years prior to start of study drug administration.
  17. Previous haematopoietic stem cell transplantation.
  18. Previous treatment with other Antibody-drug conjugateantibody-coupled drugs.
  19. Known to the drug vedicilizumab for injection and its components or to Zimberelimab injection and other monoclonal antibodies.
  20. Have any other disease, metabolic abnormality, physical examination abnormality or laboratory test abnormality.
  21. Estimated lack of patient adherence to participate in this clinical study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Disitamab Vedotin + Zimberelimab

    Disitamab Vedotin(RC48-ADC)with Zimberelimab arm

    Drug: Disitamab Vedotin · Drug: Zimberelimab

Interventions

06

What researchers measure

Primary outcomes

  1. Safety run-in :Safety(adverse event)

    to evaluate safety including adverse event rate and adverse event grade.

    Time frame: Up to approximately 2 years

  2. Dose extension period :Objective Response Rate (ORR)

    The objective response rate will be mainly analyzed by according to the RECIST 1.1 standard tumor evaluation by the investigator will be performed

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate(ORR)

    The objective response rate will be mainly analyzed by according to the RECIST 1.1 standard tumor evaluation by the investigator will be performed

    Time frame: Up to approximately 2 years

  2. Duration of Response (DOR)

    DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

    Time frame: Up to approximately 2 years

  3. Disease Control Rate(DCR)

    Proportion of patients whose tumors shrank or stabilized for a certain period of time

    Time frame: Up to approximately 2 years

  4. Progression-free survival (PFS), evaluated by the investigator

    Progression-free survival (PFS) refers to the time from the date of first administration to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

    Time frame: Up to approximately 2 years

  5. Overall survival (OS)

    Overall survival (OS) refers to the time from the date of first administration to the date of death of the subject.

    Time frame: Up to approximately 2 years

07

Study locations

1 of 12 sites recruiting
  • The first affiliated hospital of bengbu medical college
    Bengbu, Anhui 233000, China
    Not yet recruiting
    • Yuzhi Li, M.D · Contact
  • Beijing Obstetrics and Gynecology Hospital ,Capital Medical University
    Beijing, Beijing 100026, China
    Not yet recruiting
    • Jinwei Miao, M.D · Contact
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400030, China
    Not yet recruiting
    • Ying Tang, M.D · Contact
  • Guangxi Tumor Hospital
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Qingjie Zhang, M.D · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
    Not yet recruiting
    • Keqiang Zhang, M.D. · Contact
  • Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi 330008, China
    Not yet recruiting
    • Meirong Liang, M.D · Contact
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110801, China
    Not yet recruiting
    • Chunyan Wang, Ph.D · Contact
  • Shandong Cancer Hospital & Institute
    Jinan, Shandong 250117, China
    Not yet recruiting
    • Dapeng Li, M.D. · Contact
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
    Recruiting
    • Xiahua Wu, Ph.D · Contact
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300181, China
    Not yet recruiting
    • Ke Wang, M.D · Contact
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650118, China
    Not yet recruiting
    • Hongping Zhang, Ph.D · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310005, China
    Not yet recruiting
    • Xiaojuan Lv, M.D. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's planned 41 months is above that.

Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
Dec 4, 2023
StartActual
Jan 11, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06155396
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Jan 11, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 28, 2024

Study contacts

Jianmin Fang, Ph.D
Contact
Jianminfang@hotmail.com
+8610-58075763
Jianmin Fang, Ph.D
study director · RemeGen Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Disitamab vedotin · Zimberelimab

Start the discussion